Do you omit #SentinelNodeBiopsy in Women Age ≥ 65 Years with ER+ #BreastCancer ?

Prospective, observational, single center study Catherine M Dang, MD Farin Amersi

rdcu.be/dIN1k

Syed A. Ahmad
AnnalsSurgOncology

#ASCO24 ESOPEC Dr Hoeppner shows improved OS HR = 0.7 with FLOT vs CROSS regimen. FLOT also improved pCR rate 16% vs 10%. Not clear how adj Nivo would affect results.

Syed A. Ahmad The solution is MELD exception points and the expanded use of normothermic perfusion. Together they can help patients acquire better grafts and mitigate risk. This would allow us to be more aggressive with therapies like HAI as a bridge. /fin

Syed A. Ahmad Most recipients will need an aortic jump graft if they have HAI. This is morbid - it receives risk adjustment from UNOS. When combined with the livers currently used (DCD, discards, etc.) it presents a lot of combined synergistic morbidity. 2/3

Syed A. Ahmad I’ve always thought HAI has a role in bridging these patients (and ICCa patients) especially in countries with high incidence of chronic liver disease and relative graft shortage as compared to graft surplus.

Jimmy Page explains the inspiration behind Led Zeppelin’s Stairway to Heaven.

#ASCO24 - NEOPRISM showed 6 weeks of pre-op Pembrolizumab in dMMR #CRC showed high pCR and 100% 3Y DFS. How much more evidence do we need to offer this to patients with bulky dMMR #coloncancer ? ⁦Kristen Ciombor⁩ ⁦COLONTOWN⁩

Syed A. Ahmad ASCO Jordan Kharofa Shimul A. Shah Davendra Sohal IHPBA Julio Mayol Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸 Flavio G Rocha, MD, FACS, FSSO Skye C. Mayo, MD, MPH Jash Datta, MD It’s hard to say something is the standard if the vast majority of patients won’t be eligible for it.

Another tool in the toolbox and for the right patient at the right time - a powerful therapy.

Congratulations Dr. Rene Adam for RCT demonstrating improved OS with #LiverTransplant for patients with metastatic #ColorectalCancer ! Although most patients had a recurrence, OS profoundly increased. 👏🏽👏🏽👏🏽 #ASCO24

ORCHESTRA 🎻 trial shows no benefit and increased morbidity to tumor debulking compared to SOC for #mCRC with multifocal visceral disease #ASCO24

OHSU Department of Surgery OHSU Knight Cancer Institute Divya Sood OncoAlert

Is thermal ablation 🔥 equivalent to
resection🔪for <3cm, well-located #CRLM

Results of the 🇳🇱 COLLISION suggests so
ASCO #ASCO24 OncoAlert

OHSU Department of Surgery OHSU Knight Cancer Institute The Dotter Institute

#ASCO24 : Dr Rene Adam TransMET showed major OS benefit, HR =0.16 of #livertransplant in liver unresectable #CRC . Recurrences mostly ex-liver and treated in transplant arm. ⁦OncoAlert⁩ ⁦Flavio G Rocha, MD, FACS, FSSO⁩ ⁦Fight Colorectal Cancer⁩

Liver transplant🆚 chemo for unresectable CRLM

TRANSMET at #ASCO24
👥94 pts - 47 transplants x 5 years
5y OS 57% vs 13% 👉🏻HR 0.37💥

➡️Chance for prolonged (& chemo free?) survival
⚠️+++ selection, few patients eligible ultimately

Where next?

At #ASCO24 , John Byrd, MD presents on ONO-7018 for relapsed/refractory NHL & CLL in 'A phase I, first-in-human study.' Promising early results in overcoming cancer resistance. More info: uofcincycancer.center/4dZsYdz #CancerResearch

Is RFA as good as resection for small colorectal metastases? Results of the Collision Study presented at ⁦ASCO⁩ #ASCO24

⁦Jordan Kharofa⁩ ⁦Shimul A. Shah⁩ ⁦Flavio G Rocha, MD, FACS, FSSO⁩ ⁦Skye C. Mayo, MD, MPH⁩ ⁦Hop S. Tran Cao⁩ ⁦⁩ ⁦Julio Mayol⁩ ⁦Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸⁩

Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study ⁦The Lancet Oncology⁩ thelancet.com/journals/lanon…

Hyperthermic intraperitoneal chemotherapy in colorectal cancer ⁦BJS Open⁩ academic.oup.com/bjsopen/articl…